aiPTO TechBio

The supplied evidence does not establish the identity, business, products, ownership, or history of aiPTO TechBio. The supplied article concerns Thrixel, a 3D generation platform, and does not provide evidence about aiPTO TechBio. Further review is needed before a commercial brand profile can be completed.

No reliable, relevant evidence about aiPTO TechBio's history was supplied. The article in the evidence describes Thrixel and cannot be used to establish milestones or history for aiPTO TechBio.

• 2026.10.08

  Reported2026.10.08

  aiPTO TechBio unveils DELPHAI virtual tumor model with #1 benchmark ranking[1]aiPTO TechBio 发布位列基准测评第一的 DELPHAI 虚拟肿瘤模型finanznachrichten.de

  aiPTO TechBio released a preprint unveiling DELPHAI (Deep Explainable Perturbation Heterogeneity-Aware Inference), its virtual tumor model for perturbation prediction. The company reported that DELPHAI achieved the #1 ranking on differentially expressed gene (DEG) recovery in two independent benchmarking frameworks (Wei et al., Nature Methods 2026; Radig et al., Genome Biology 2026), outperforming state-of-the-art virtual cell models, and that it predicts drug responses for previously unseen, out-of-distribution patients with biologically explainable outputs.

Read more

1. 1aiPTO TechBio 发布位列基准测评第一的 DELPHAI 虚拟肿瘤模型finanznachrichten.de